Prognostic Value of the Quantitative Metabolic Volumetric Measurement on 18F-FDG PET/CT in Stage IV Nonsurgical Small-cell Lung Cancer
Academic Radiology, 12/09/2011Liao S et al.
Baseline whole–body (WB) metabolic tumor burden, as measured with metabolic tumor volume (MTV) and total lesion glycolysis (TLG), is a prognostic measurement in patients within Stage IV non–small–cell lung cancer (NSCLC) with low interobserver variability. This study also suggests pretreatment MTV and TLG measurements may be used to further stratify patients with Stage IV NSCLC and are better prognostic measures than SUVmax and SUVmean measurements.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.